Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics
摘要:
In this paper, we report the synthesis of novel, potential antipsychotic coumarin derivatives combining potent dopamine D-2, D-3 and serotonin 5-HT1A 5-HT(2)A receptors properties. We describe the structure activity relationship that leads us to the promising derivative: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin-1-yl)butoxy)-6-methyl-2,3-dihydrocyclopenta[c]chromen-4(1H)-one 27. The unique pharmacological features of compound 27 are a high affinity for dopamine D-2, D-3 and serotonin 5-HT1A, 5-HT2A receptors, together with a low affinity for H-1 receptor (to reduce the risk of obesity under chronic treatment). In animal models, compound 27 inhibited apomorphine-induced climbing and MK-801-induced hyperactivity without observable catalepsy at the highest dose tested. In particular, compound 27 was more potent than clozapine. (C) 2014 Elsevier Masson SAS. All rights reserved.
ALICYCLIC[C] BENZOPYRONE DERIVATIVES AND USES THEREOF
申请人:Zhang Guisen
公开号:US20140171442A1
公开(公告)日:2014-06-19
Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED
50
is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED
50
is higher and therapeutic index is greater in animal models of catalepsy.